<DOC>
	<DOCNO>NCT01914393</DOCNO>
	<brief_summary>This open-label , 104-week , multicenter , extension study design evaluate long-term safety , tolerability effectiveness flexibly dose lurasidone ( 20 , 40 , 60 80 mg/day ) pediatric subject complete 6-week treatment period precede study , D1050301 , D1050325 , D1050326</brief_summary>
	<brief_title>Pediatric Open-Label Extension Study</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Lurasidone Hydrochloride</mesh_term>
	<criteria>Written inform consent parent ( ) legal guardian ( ) sufficient intellectual capacity understand study support subject ' participation study procedure must obtain subject emancipate . In accordance Institutional Review Board ( IRB ) Independent Ethics Committee ( IEC ) requirement , subject complete inform assent developmentally appropriate , participate study conduct studyspecific procedure . Subject complete Study D1050301 ( Visit 9 ) OR Subject complete Study D1050325 ( Visit 9 ) OR Subject complete Study D1050326 ( Visit 8 ) Subject judge investigator appropriate participation 104week clinical trial outpatient set involve openlabel lurasidone treatment , able comply protocol . A reliable informant ( eg , parent , legal guardian , caregiver ) must available accompany subject visit . For subject enter Study D1050325 , reliable caregiver must also oversee administration study drug throughout study Females participate study : unable become pregnant ( eg , premenarchal , surgically sterile , etc . ) OR practice true abstinence ( consistent lifestyle ) must agree remain abstinent signing informed consent least 7 day last dose study drug take ; OR sexually active willing use medically effective method birth control ( eg , male use condom female use condom , diaphragm , contraceptive sponge , spermicide , contraceptive pill , intrauterine device ) signing informed consent least 7 day last dose study drug take . Males must willing remain sexually abstinent ( consistent lifestyle ) use effective method birth control ( eg , male use condom female use condom , diaphragm , contraceptive sponge , spermicide , contraceptive pill , intrauterine device ) signing informed consent least 7 day last dose study drug take . Subject consider investigator imminent risk suicide . Exhibits evidence moderate severe extrapyramidal symptom , dystonia , tardive dyskinesia , moderate severe movement disorder . Severity determine investigator .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Autism</keyword>
	<keyword>Lurasidone</keyword>
	<keyword>Latuda</keyword>
</DOC>